In a groundbreaking public health initiative, the NHS has officially launched its first-ever vaccination program against respiratory syncytial virus (RSV) for older adults and pregnant women. This marks a significant step in the fight against a virus that has become a growing concern, particularly for infants and the elderly.
With RSV cases on the rise among young children in recent years, this new vaccination effort is poised to make a substantial impact. A recent study suggests that the program could prevent approximately 5,000 hospitalizations and 15,000 A&E visits among infants, significantly easing the winter burden on pediatric units across the UK. RSV remains one of the leading causes of infant mortality worldwide, making this initiative even more critical.
Pregnant women can now receive the vaccine starting at 28 weeks of pregnancy, offering protection to their unborn children. The vaccine is also available to adults aged 75 to 79, a group particularly vulnerable to the virus.
Research indicates that for older adults, the vaccination campaign could prevent:
– 2,500 hospital admissions
– 15,000 GP visits
– 60,000 cases of RSV illness
“After months of preparation from our hardworking staff, we are now offering the RSV vaccine to pregnant women and older adults at greatest risk, helping to protect lives and ease pressures across the NHS as winter approaches,” said Steve Russell, NHS England’s National Director for Vaccinations.
Global data has shown that the vaccine reduces the risk of severe lung infections by 70% in the first six months of life. Over 100,000 women in the U.S. have already benefited from this protection.
Public Health Minister Andrew Gwynne MP emphasized the importance of the new program: “RSV is preventable, and it is crucial that we take the necessary steps to protect ourselves and our loved ones. This vaccine program will reduce thousands of hospitalizations and save precious lives.”
Professor Dame Jenny Harries, CEO of the UK Health Security Agency (UKHSA), highlighted the significance of the initiative: “The rollout of this vaccine is a truly positive moment for public health, offering huge opportunities to prevent severe illness in those most vulnerable and helping to ease NHS winter pressures.”
Read More: Click Here
